drugset / Trial / NCT00059215
A Trial of CS-747 (Prasugrel) Compared With Clopidogrel in Patients Undergoing Percutaneous Coronary Intervention (PCI)
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this study is to evaluate the effects of a drug known as CS-747 (also known as prasugrel) on subjects having a procedure called a percutaneous coronary intervention (also referred to as PCI) in which a doctor will attempt to open a blocked vessel (or vessels) in the heart using a catheter (a long thin tube) that has a small balloon on the end. In many cases, patients who have this procedure receive a stent, a small wire spring that helps keep the vessel open.
Timeline
- Start
- 2003-04
- Primary completion
- 2004-01
- Completion
- 2004-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Clopidogrel | Small molecule | 75 mg | Oral |
| Subject | Prasugrel | Small molecule | 7.5 mg | Oral |
| Subject | Prasugrel | Small molecule | 10 mg | Oral |
| Subject | Prasugrel | Small molecule | 15 mg | Oral |